Asia-Pacific Hepatitis B Infection Market –Industry Trends and Forecast to 2031

Asia-Pacific Hepatitis B Infection Market Analysis and Insights

Data Bridge Market Research analyzes that the  Asia-Pacific hepatitis B infection market is expected to reach USD 6.52 billion by 2031 from USD 4.03 billion in 2023, growing with a CAGR of 6.2% in the forecast period of 2024 to 2031.

Market Definition

Asia-Pacific hepatitis B infection market refers to the healthcare sector focused on the diagnosis, treatment, prevention, and management of hepatitis B virus (HBV) infections. This market encompasses a wide range of products and services, including vaccines, antiviral drugs, diagnostic tests, immune modulators, and therapeutics aimed at addressing both acute and chronic forms of hepatitis B. Hepatitis B is a highly infectious liver disease caused by the HBV, which can lead to severe health complications like cirrhosis, liver failure, and hepatocellular carcinoma. The market includes pharmaceutical companies, biotechnology firms, diagnostic service providers, healthcare facilities, and research institutions working to develop advanced treatment solutions. The increasing prevalence of hepatitis B Asia-Pacific, coupled with rising awareness and government initiatives to curb its spread, are key drivers of market growth. Also, technological advancements in diagnostic tools and novel therapies, such as nucleoside analogs and immunomodulatory agents, are expanding the treatment landscape. Regional variations in HBV prevalence, access to healthcare, and vaccination coverage also influence market dynamics, with developing countries presenting untapped growth opportunities.

Asia-Pacific Hepatitis B Infection Market Dynamics.

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:      

Driver

Increasing Prevalence of Hepatitis B Infections

 The increasing prevalence of Hepatitis B infections serves as a significant driver in the Hepatitis B infection market by creating a growing demand for effective diagnostic tools, vaccines, and antiviral treatments. As Hepatitis B is a major cause of liver diseases such as cirrhosis and liver cancer, the rising infection rates, particularly in regions with inadequate healthcare infrastructure, have heightened the need for prevention, management, and treatment options. The spread of chronic Hepatitis B infections, especially in low- and middle-income countries where awareness and vaccination programs are less established, further amplifies the market for immunization, antiviral therapies, and advanced diagnostic techniques. Also, pharmaceutical companies are investing in research and development of newer, more efficient antiviral drugs and vaccines to address the evolving strains of the virus. The rise in both acute and chronic cases, particularly in high-risk populations, has put pressure on healthcare systems to invest in improved diagnostics, vaccines, and antiviral therapies.

Restraint

• Side Effects and Drug Resistance

Side effects and drug resistance serve as significant restraints in the Hepatitis B infection market by limiting the effectiveness and long-term use of available therapies. Many antiviral drugs used to treat Hepatitis B can cause adverse effects such as fatigue, nausea, liver toxicity, and kidney damage, which can lead to poor patient adherence and treatment discontinuation. This not only hampers the success of treatment but also reduces the overall demand for certain medications. Furthermore, the development of drug-resistant strains of the Hepatitis B virus presents another major challenge, as it reduces the efficacy of current antiviral therapies and necessitates the constant development of new drugs. As resistance to existing treatments increases, it creates barriers for healthcare providers in managing the infection effectively, limiting the market's growth potential. These challenges contribute to hesitancy in prescribing long-term antiviral therapies, slowing the adoption of certain medications and thereby restraining market expansion

Opportunity

 Rising New Drug Releases and Increasing New Drug Permits for Hepatitis B

The hepatitis B market is experiencing significant growth, driven by several key factors including the rising number of new drug releases and an increase in new drug permits. The surge in drug approvals is partly a response to the persistent need for more effective antiviral therapies and vaccines to manage and potentially eradicate hepatitis B. This trend is evident from the increased investments in research and development by major pharmaceutical companies, which are focusing on innovative treatment options that offer improved efficacy, fewer side effects, and enhanced patient compliance. Additionally, advancements in drug delivery systems and the development of combination therapies have contributed to the expansion of the market. The growth in market share for hepatitis B drugs is also supported by the increasing prevalence of the disease, particularly in regions with high infection rates such as Asia-Pacific and sub-Saharan Africa. As new therapies become available and the market becomes more competitive, financial growth is expected to be robust, with projections indicating a substantial increase in market value over the coming years. This growth is underpinned by rising healthcare expenditure, broader healthcare access, and heightened awareness about the importance of hepatitis B management. The market is likely to see continued expansion as new players enter the field, existing companies innovate, and healthcare systems around the world prioritize hepatitis B treatment.

Challenge

•  The Cost of Hepatitis B Treatments is High

The high cost of hepatitis B treatments presents significant challenges for the market. One of the primary factors contributing to this challenge is the complexity of developing antiviral drugs and immunomodulators that effectively manage the virus without causing severe side effects. This complexity requires extensive research, clinical trials, and regulatory approvals, all of which drive up the price of the final product. Additionally, the ongoing nature of treatment for chronic hepatitis B means that patients often face long-term costs, which can be prohibitively expensive, particularly in regions with limited access to healthcare subsidies or insurance coverage.

Another challenge is the limited availability of generic versions of hepatitis B drugs. Many of the more effective treatments remain under patent protection, allowing pharmaceutical companies to maintain high prices. This lack of competition further exacerbates the financial burden on patients, healthcare systems, and governments. Moreover, the development of newer treatments, such as those aimed at complete viral eradication, is still in the early stages, with no immediate prospects for significantly lowering treatment costs in the near future.

• In May 2022, according to the article published by the Hepatitis B Foundation , the estimated 300 million people living with hepatitis B, only 10% have been diagnosed, and just 22% of those diagnosed receive antiviral treatments. In Africa, the situation is even more dire, with only 2% of individuals with chronic hepatitis B receiving a diagnosis and just 0.1% receiving treatment. A significant barrier to treatment is the cost

Recent Developments

• In September 2024, Gilead Sciences and Genesis Therapeutics announced a strategic collaboration to discover and develop novel small molecule therapies using Genesis’ GEMS AI platform. Gilead gained exclusive rights to develop and commercialize products from this partnership
• In July 2024, Gilead Sciences, Inc. presented research data, showcasing long-term efficacy and safety of Biktarvy in diverse HIV populations, including Hispanic/Latine individuals and older adults with comorbidities. Investigational once-daily and weekly dosing regimens were also highlighted
• In February 2024, GSK completed its acquisition of Aiolos Bio, including the promising AIO-001 monoclonal antibody for severe asthma. GSK paid USD 1000 million upfront and up to USD 400 million in milestone payments, expanding its respiratory biologics portfolio

Asia-Pacific Hepatitis B Infection Market Scope

  Asia-Pacific hepatitis B infection market is categorized into two notable segments which are based on the type and treatment. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

• Chronic
• Acute

On the basis of type, the market is segmented into chronic and acute.

 Treatment

• Vaccine
•  Antiviral Drugs
• Immune Modulator Drugs
• Surgery

On the basis of treatment, the market is segmented into vaccine, antiviral drugs, immune modulator drugs, and surgery.

Asia-Pacific Hepatitis B Infection Market Regional Analysis/Insights

Asia-Pacific hepatitis B infection market is categorized into two notable segments which are based on the type and treatment. 

The country covered in this market report are China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific.

China is expected to dominate the market due to rising new drug releases and increasing new drug permits for hepatitis B.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and, Asia-Pacific Hepatitis B Infection Market Dynamics Market Share Analysis

Asia-Pacific Hepatitis B infection market dynamics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.

Some of the major market players operating in the market are Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), Merck Sharp and Dohme Corp. (U.S.), Novartis AG (Switzerland), Arrowhead Pharmaceuticals Inc. (U.S.), Arbutus Biopharma (Canada), Teva Pharmaceuticals, Inc. (Israel), Zydus Pharmaceuticals (India), Aurobindo Pharma (India), Lupin Pharmaceuticals, Inc. (India).   

SKU-72952